PDCD1 and neoplasm: A Phase I trial (NCT02791334) demonstrated that combining a TIM-3 inhibitor (LY3321367) with anti-PD-L1 (LY3300054) therapy did not compromise the safety or tolerability of either treatment, and the results suggested numerically higher response rates in the anti–PD-1/PD-L1 inhibitor-naïve microsatellite instability-high/mismatch repair-deficient tumor group (ORR: 45%; DCR: 70%; 1-year OS: 64%, vs. ORR: 33%; DCR: 60%; 1-year OS: 71%) [169].